An observational study in Alzheimer Disease, sponsored by IRCCS San Raffaele Roma. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by IRCCS San Raffaele Roma · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.
Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 16th largest by enrollment of the 36 observational ones that give a count, is one of 16 that started in 2023, is one of 36 observational ones, and was the 166th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
University of Siena · Sites in Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 47 · Phase 3 75 · Phase 4 2
First in 2003; this study’s year is marked. 16 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 328 across the 170 interventional studies, 273 across the 36 observational. Of the 125 that completed or were terminated, 64 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 206 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele Roma is the lead sponsor of 71 studies on the registry; 25 are open to participants now.
IRCCS San Raffaele Roma has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Alzheimer Disease with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06179680IRCCS Policlinico S. DonatoWhite Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease | 2026-12 |
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 206 studies in Alzheimer Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention. Studying the etiopathogenesis and pathophysiological mechanisms of AD is a necessary prerequisite for the development of new biomarkers and innovative therapies. Contrarily to anatomical structures, cortical connectivity networks are already deteriorated in early AD and could be a reliable marker of early cognitive decline. Our aim is to characterize the neurophysiological parameters in mild AD, in patients with mild cognitive impairment and in matched healthy subjects to identify discriminating criteria. Concurrently, the study of AD onset and progression in a mouse model, will allow evaluating the causal effect of inflammation on disease progression and to develop a new class of biomimetic anti-inflammatory nanoparticles formulated to have the intrinsic ability to induce brain's activated microglia to an M2 phenotype.
100 AD and 100 MCI individuals from the dementia clinical centres of North Sardinia and local sections of patients¿ associations and 100 HC will be recruited for the study. To investigate past/present health status and medications, baseline medical screening will be performed by general clinical and anthropometric examinations
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Identification of Disease-Associated Phenotypes in MCI and AD
Time frame: through study completion, an average of 1 year
Identification of Disease-Associated Early Interventions in MCI and AD
Time frame: through study completion, an average of 1 year
Predictive Power of EEG-Based Brain Network Analyses for MCI to AD Conversion
EEG power spectral density
Time frame: through study completion, an average of 1 year
Evaluation of Targeting Efficiency of Activated vs Native Leukosomes in Brain Inflammation
Time frame: through study completion, an average of 1 year
Evaluation Trafficking Kinetics of Activated vs Native Leukosomes in Brain Inflammation
Time frame: through study completion, an average of 1 year
Assessment of Activated Leukosomes in Inducing Anti-Inflammatory Polarization of Macrophages
Time frame: through study completion, an average of 1 year
Assessment of Activated Leukosomes in Glial Cells
Time frame: through study completion, an average of 1 year
Ran from May 2023 to primary completion in Dec 2025, 31 months.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 31 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
Primary completion moved once since we started tracking on Sep 25, 2026: May 2025 → Dec 2025, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS San Raffaele Roma